666-03-006 ISMRM Abstract

Peripheral serum metabolomic alterations in Schizophrenia: a preliminary NMR-based metabolomics study

Primary: Preclinical Animal & in vitro MR - Biomarkers

Secondary: Neuro - Psychiatric Disorders

666-03-006 · Neuro-Biomarkers · Thursday, 14 May, 1:40 PM–2:35 PM · Digital Posters Row G

Keywords: Biomarkers Metabolomics Treatment-Resistant Schizophrenia In-vitro NMR Spectroscopy

Accepted

Uma Sharma¹, Tanmay Dey Sarkar¹, Gagan Hans²

¹Department of Nuclear Magnetic Resonance (NMR), All India Institute of Medical Sciences, New Delhi, India

²Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, India

Presenting Author: Durgesh K Dwivedi

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Tasić L, Pontes JG, Carvalho M, et al. Metabolomics and lipidomics analyses by ¹H nuclear magnetic resonance of schizophrenia patient serum reveal potential peripheral biomarkers for diagnosis. Schizophr Res. 2017;185:182-189. doi:10.1016/j.schres.2016.12.024. [doi]

2. Lin C, Wang X, Zhang J, et al. Serum metabolic signatures of schizophrenia patients complicated with hepatitis B virus infection: a ¹H NMR-based metabolomics study. Front Psychiatry. 2022;13:998709. doi:10.3389/fpsyt.2022.998709. [doi]

3. Simić K, Todorović N, Trifunović S, et al. NMR metabolomics in serum fingerprinting of schizophrenia patients in a Serbian cohort. Metabolites. 2022;12(8):707. doi:10.3390/metabo12080707. [doi]

4. Emwas AH, Roy R, McKay RT, et al. NMR spectroscopy for metabolomics research. Metabolites. 2019;9(7):123. doi:10.3390/metabo9070123. [doi]

5. Orešič M, Tang J, Seppänen-Laakso T, et al. Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med. 2011;3(3):19. doi:10.1186/gm233. [doi]

6. Lennox BR, Xiong W, Waters P, et al. The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis. Mol Psychiatry. 2022;27:4722-4730. doi:10.1038/s41380-022-01784-4. [doi]

7. Jiao S, Cao T, Cai H. Peripheral biomarkers of treatment-resistant schizophrenia: genetic, inflammation and stress perspectives. Front Pharmacol. 2022;13:1005702. doi:10.3389/fphar.2022.1005702. [doi]

8. Cai HL, Xuan J, Zheng P, et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. J Proteome Res. 2012;11(8):4338-4350. doi:10.1021/pr300459d. [doi]

9. Grover S, et al. Pharmacometabolomics-guided clozapine therapy in treatment-resistant schizophrenia: preliminary exploration of future too near. Asian J Psychiatr. 2022;73:103135. doi:10.1016/j.ajp.2022.103135. [doi]

10. He Y, Yu Z, Giegling I, et al. Schizophrenia shows a unique metabolomics signature in plasma. Transl Psychiatry. 2012;2(8):e149. doi:10.1038/tp.2012.76. [doi]

11. Kopylov AT, Stepanov AA, Butkova TV, et al. Consolidation of metabolomic, proteomic, and GWAS data in a connective model of schizophrenia. Sci Rep. 2023;13(1):2139. doi:10.1038/s41598-023-29117-7. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/666-03-006